We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Higher Histone Levels Associated with Thrombocytopenia

By LabMedica International staff writers
Posted on 09 Mar 2016
Thrombocytopenia is observed in approximately 30% to 40% of patients in the intensive care unit (ICU) concomitant with poor outcomes and an association with histones has been examined. More...


Thrombocytopenia is a blood disease characterized by an abnormally low number of platelets in the blood and histones induce profound thrombocytopenia in mice and are associated with organ injury when released following extensive cell damage in patients who are critically ill.

Scientists at the University of Liverpool (UK) carried out a case control study on included 56 patients with thrombocytopenia and 56 controls with normal platelet counts who were admitted to the ICU of the Royal Liverpool University Hospital (Liverpool, UK) between June 2013 and January 2014. Thrombocytopenia was defined as platelet count less than 150,000/103 µL or greater than 25% decrease or both with in the first 96 hours of admission to the ICU. Plasma histones were measured and daily levels and compared between the thrombocytopenic patients and non-thrombocytopenic controls.

The investigators found that histones circulated in the majority of thrombocytopenic patients and the histone levels were 2.5-fold to 5.5-fold higher than in non-thrombocytopenic controls. There was a significant association between high levels of histones at admission and subsequent decline in platelet counts among thrombocytopenic patients. High admission histone levels were associated with moderate to severe thrombocytopenia and development of clinically important thrombocytopenia.

The authors concluded that circulating histones are potential markers of disease severity, and the association with thrombocytopenia may reflect this. Nevertheless, the novel associations reported in the study extend previous reports demonstrating profound thrombocytopenia following histone infusion into mice and suggest that, if confirmed, circulating histones may be valuable in predicting or monitoring thrombocytopenia in patients who are critically ill.” The study was published on February 22, 2016, in the Journal of the American Medical Association.

Related Links:

University of Liverpool
Royal Liverpool University Hospital



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.